Product Information
LAMIVUDINE-ZIDOVUDINE TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $0.7707 per EA under NDC 65862003660. Its NADAC has been published 256 times since Nov 10, 2021.
FDA first approved this application on May 5, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150; 300 mg/1; mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862003660
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LAMIVUDINE; ZIDOVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA077558FDA Approved
5/5/2017
TE Code
AB
On Market Since
5/5/2017
Pharmacological Classes
Price Statistics
The NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has been published 256 times since Nov 10, 2021, and over the history we have for it it has declined 21.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7707 per EA |
|---|---|
| All-time high | $0.9767 (Dec 15, 2021) |
| All-time low | $0.5570 (Jan 21, 2026) |
| 52-week high | $0.7707 |
| 52-week low | $0.5570 |
| Median price | $0.6464 |
| Average price | $0.6908 |
| Largest weekly change | -35.6% (Dec 22, 2021) |
| Weeks tracked | 256 |
| Tracking since | Nov 10, 2021 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lamivudine and Zidovudine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LAMIVUDINE-ZIDOVUDINE TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE-ZIDOVUDINE TABLET, manufactured by Aurobindo Pharma Limited, is $0.7707 per EA (NDC 65862003660), effective Sep 30, 2026.
How has the price of LAMIVUDINE-ZIDOVUDINE TABLET changed over time?
Over the history we have for it, the NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has declined 21.1%. It has been tracked across 256 weekly CMS publications since Nov 10, 2021.
What are the highest and lowest recorded NADAC prices for LAMIVUDINE-ZIDOVUDINE TABLET?
Since Nov 10, 2021, the NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has ranged from a low of $0.5570 (Jan 21, 2026) to a high of $0.9767 (Dec 15, 2021), with a median of $0.6464 per EA.
Are there cheaper alternatives to LAMIVUDINE-ZIDOVUDINE TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LAMIVUDINE-ZIDOVUDINE TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures LAMIVUDINE-ZIDOVUDINE TABLET?
LAMIVUDINE-ZIDOVUDINE TABLET (NDC 65862003660) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.